CHARTWELL NEWS
  • INDEPENDENT FINANCIAL NAMES MARY BAILEY CHIEF COMPLIANCE OFFICER

    Chartwell Partners is pleased to announce the placement of Mary Bailey as Chief Compliance Officer at Independent Financial.  Bailey will be responsible for aligning the compliance function and strategy of the institution to its ambitious growth goals while developing, executing and monitoring the compliance strategy enterprise wide. Most recently, Bailey served in compliance consulting roles…

  • BioCryst Pharmaceuticals Appoints Salisa Hauptmann, MPH as SVP, Regulatory Affairs

    Chartwell Partners is pleased to announce the appointment of Salisa Hauptmann, MPH, as Senior Vice President, Regulatory Affairs for BioCryst Pharmaceuticals, a company pioneering the discovery, development and commercialization of oral, small molecule medicines to treat rare diseases. Salisa brings more than 25 years of global regulatory expertise to BioCryst, including significant work with rare,…

  • Rare Disease Biotech Company, EryDel, names Esin Kosal, PhD as SVP, Regulatory Affairs

    Chartwell Partners is pleased to announce the recruitment of Esin Kosal, PhD as SVP, Regulatory Affairs for EryDel SpA, a global biotechnology company utilizing its proprietary red blood cell drug delivery technology to encapsulate small and large molecules into a patient’s own red blood cells which are then reinfused into that patient in a fast,…